Design of orally bioavailable, symmetry-based inhibitors of HIV protease
- 30 September 1994
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 2 (9) , 847-858
- https://doi.org/10.1016/s0968-0896(00)82036-2
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 proteaseJournal of the American Chemical Society, 1994
- Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease InhibitorsScience, 1994
- Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transportJournal of Medicinal Chemistry, 1994
- STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASEAnnual Review of Biochemistry, 1993
- Discovery of a Peptide-Based Renin Inhibitor with Oral Bioavailability and EfficacyScience, 1992
- HIV protease: a novel chemotherapeutic target for AIDSJournal of Medicinal Chemistry, 1991
- Design, Activity, and 2.8 Å Crystal Structure of a C 2 Symmetric Inhibitor Complexed to HIV-1 ProteaseScience, 1990
- Rational Design of Peptide-Based HIV Proteinase InhibitorsScience, 1990
- Novel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy TransferScience, 1990
- Reactions of 2-acyloxyisobutyryl halides with nucleosides. I. Reactions of model diols and of uridineJournal of the American Chemical Society, 1973